Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant

Allogeneic transplantation is used to treat many malignant and non-malignant diseases. The investigators and others have shown that less toxic preparative regimens (reduced intensity or 'mini' transplants) allow reliable allogeneic engraftment and durable remissions, significantly broadening the population of patients who may be offered this therapy to those who are older and more infirmed. The field is now focusing on the period post transplant for approaches to immune recovery leading to improved outcomes.

The primary objective of this registry is to catalogue data from patients who undergo standard of care reduced intensity allogeneic transplantation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hodgkin's Disease Anemia Anemia, Refractory Anemia, Refractory, with Excess of Blasts Bone Marrow Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hodgkin Disease Immune System Diseases Immunoproliferative Disorders Leukemia Lymphatic Diseases Lymphoma Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Myelodysplasia Myelodysplastic Syndromes Myeloma Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Non Hodgkin's Lymphoma

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Duke University Health System

Durham, North Carolina, 27710, United States

About this study

Subjects will have toxicity monitored and reported per the Center for International Blood and Marrow Transplant Research (CIBMTR) program standard and as required by law for bone marrow transplant (BMT) reporting in the USA. Data will be collected from physical exam, laboratory studies, radiographs that are performed for clinical purposes. The tests and procedures are not in addition or in excess of our standards for allogeneic transplant outside of this registry. Data about donors will also be collected.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Recipient Inclusion Criteria:

Subjects ≥ 18 years of age undergoing a reduced intensity allogeneic transplant

Exclusion criteria

Subjects < 18 years of age
Subjects not undergoing nonmyeloablative or ablative allogeneic transplant

Treatment and study plan

Primary outcomes

Catalogue Data

Time frame: 1 year

Catalogue data from subjects who undergo standard of care reduced intensity allogeneic transplantation.

Sponsors and collaborators

Lead sponsor

Duke University

Other

Registry information

Official study title

Registry Study of T Cell Depleted Allogeneic Non-Myeloablative Stem Cell Transplant Recipients

Important dates

Study start: 2013
Primary completion: 2016
Study completion: 2016
First posted: Jul 22, 2013
Registry last updated: May 5, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed